Results 191 to 200 of about 76,806 (261)

Case Report: A case of jejunal T-cell non-Hodgkin lymphoma with secondary bone involvement presenting as gastrointestinal perforation. [PDF]

Front Med (Lausanne)
Gao Y, Sun T, Sun J, Lu F, Wang T, Han J.   +5 more
europepmc   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 9, Page 2177-2189, September 2026.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

The IL‐10/IL‐6 Ratio and the Risk Score: Two Cytokines‐Based Predictors for Malignancy‐Associated Hemophagocytic Lymphohistiocytosis in Adults (M‐HLHa)

American Journal of Hematology, Volume 101, Issue 9, Page 2214-2224, September 2026.
ABSTRACT The predictive value of cytokines (CK) for malignancy‐associated adult hemophagocytic lymphohistiocytosis (M‐HLHa) remains uncertain. We evaluated a cytokine‐based Risk Score (RS) and the IL‐10/IL‐6 Ratio to predict M‐HLHa. Adult patients (n = 112) from the French HLH cohort (NCT02113917) with complete data for nine key HLH related CK measured
Coralie Bloch, Stephanie Chhun, Nanthara Sritharan, Marine Gil, Raphael Lhote, Marouane Boubaya, Olivier Lambotte, David Launay, Claire Larroche, Estibaliz Lazaro, Francois Liffermann, Marc Michel, Jean‐Marie Michot, Pierre Morel, Louis Terriou, Geoffrey Urbansk, Jean‐Francois Viallard, Morgane Cheminant, Felipe Suarez, Yves Lepelletier, Geneviève de Saint Basile, Olivier Hermine, the French HLH Study Group, Coralie Bloch, Jean Philippe Jais, Francois Liffermann, Pierre Morel, Morgane Cheminant, Felipe Suarez, Olivier Hermine, Fabrice Bonnet, Pascal Godemer, Damaj Gandhi, Olivier Fain, Olivier Lambotte, David Launay, Louis Terriou, Claire Larroche, Estibaliz Lazaro, Jean‐Francois Viallard, Francois Liffermann, Olivier Lortholary, Marc Michel, Jean‐Marie Michot, Pierre Morel, Frederic Pene, Antoinette Perlat, Geoffrey Urbanski   +47 more
wiley   +1 more source

<i>Cladosporium cladosporioides</i> Fungemia in a Patient with Non-Hodgkin Lymphoma: An Extremely Rare Case and Review of the Literature. [PDF]

Reports (MDPI)
Niyazi D, Daskalova N, Micheva I, Stoeva T.   +3 more
europepmc   +1 more source

Clinical Predictors of Response in Chronic Graft‐Versus‐Host Disease: Results From the “Predicting the Quality of Response to Specific Treatments (PQRST)” Trial

American Journal of Hematology, Volume 101, Issue 9, Page 2280-2287, September 2026.
ABSTRACT Despite significant progress in chronic GVHD therapies, challenges remain in understanding pleomorphic phenotypes and varying responses to treatment. The aim of this study was to identify predictors of treatment response. We conducted a prospective, observational cohort study of patients beginning first‐, second‐, or third‐line systemic ...
Betty K. Hamilton, Lynn Onstad, Paul A. Carpenter, Joseph Pidala, George Chen, Corey Cutler, Najla El Jurdi, Nosha Farhadfar, Mark Juckett, Carrie L. Kitko, Catherine J. Lee, Stephanie J. Lee   +11 more
wiley   +1 more source

HERV-K Envelope Induce a Humoral Response in Non-Hodgkin Lymphoma Patients. [PDF]

Curr Microbiol
Cossu I, Ruberto S, Filippi E, Simula ER, Noli M, Mottula A, Fozza C, Sechi LA.   +7 more
europepmc   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, Volume 120, Issue 3, Page 614-638, September 2026.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source

Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review. [PDF]

J Patient Rep Outcomes
Schroer J, Bröckelmann PJ, Salek S, Ionova T, Laane E, Oliva EN, Monsef I, Skoetz N, Csenar M.   +8 more
europepmc   +1 more source

Non-Hodgkin Lymphoma and Tuberculosis Coexisting in the Same Cervical Lymph Node: A Case Report. [PDF]

Cureus
Taha A, Alzhrani S, Aljafari N, Aljadani BA, Al-Rashdi A, Almuntashiri AA, Alkhalifah KM, Bahshwan W.   +7 more
europepmc   +1 more source

Integrated Model for Predicting Cancer Therapy-Related Cardiac Dysfunction in Non-Hodgkin Lymphoma. [PDF]

Biomedicines
Bursacovschi D, Arnaut O, Ochisor V, Mihalache G, Baltaga R, Iacomi V, Robu M, Revenco V.   +7 more
europepmc   +1 more source